Change in study design and required approval [Regulatives / Guidelines]

posted by Karthikeyan – India, 2013-07-15 15:31 (4732 d 19:07 ago) – Posting: # 10975
Views: 3,874

Dear Docksr;

Amendment in the basic study design should be notified to DCGI and approval is required before teh study initiation.

And there is another clause;
if you have three way with two sequence (T1RT2 & RT1T2); you can initiate the study and terminate the last period (T2). reason for terminating the last period should be stated in report, and the section change in conduct of the study to be updated with a deviation filled.

Regards

K@K


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
282 visitors (0 registered, 282 guests [including 25 identified bots]).
Forum time: 10:38 CEST (Europe/Vienna)

It requires a very unusual mind
to undertake the analysis of the obvious.    Alfred North Whitehead

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5